Prognostic factors of early recurrence after complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

Table 1 Demographic and clinical data of the study population

Characteristic	All	< 1 yr group, n = 39	≥ 1 yr group, n = 41	P value
Age in yr
Mean ± SD	55.21 ± 11.48	52.74 ± 12.36	57.56 ± 10.18	0.060
Median (mix, max)	58 (22, 74)	56 (22, 73)	59 (36, 74)	0.102
Sex
Male	27 (33.7)	15 (38.5)	12 (29.3)	0.480
Female	53 (66.3)	24 (61.5)	29 (70.7)
BMI in kg/m2
Mean ± SD	24.20 ± 3.98	24.05 ± 4.22	24.34 ± 3.77	0.746
Hypertension	23 (28.8)	11 (28.2)	12 (29.3)	1.000
Diabetes mellitus	16 (20.0)	8 (20.5)	8 (19.5)	1.000
Clinical presentation
Primary	35 (43.7)	18 (46.2)	17 (41.5)	0.822
Recurrence	45 (56.3)	21 (53.8)	24 (58.5)
Ascites presentation	2 (2.5)	1 (2.6)	1 (2.4)	1.000
Previous systemic therapy
Never	20 (25.0)	8 (20.5)	12 (29.3)	0.443
1st line or more	60 (75.0)	31 (79.5)	29 (70.7)
Extraperitoneal oligometastasis
Liver	13 (16.3)	7 (17.9)	6 (14.6)	0.767
Lung	3 (3.8)	1 (2.6)	2 (4.9)	1.000
Extraperitoneal LN	3 (3.8)	1 (2.6)	2 (4.9)	1.000
Skin	4 (5.0)	3 (7.7)	1 (2.4)	0.353
Vagina	2 (2.5)	1 (2.6)	1 (2.4)	1.000
Cancer types				0.540
Colorectal	42 (52.5)	22 (56.4)	20 (48.8)
Ovary	22 (27.5)	9 (23.1)	13 (31.7)
Platinum-sensitive	11 (13.8)	3 (7.7)	8 (19.5)
Platinum-resistance	11 (13.8)	6 (15.4)	5 (12.2)
Gastric	12 (15.0)	7 (17.9)	5 (12.2)
Appendix, high grade	4 (5.0)	1 (2.6)	3 (7.3)
Histology grade				0.020a
1	10 (12.4)	1 (2.6)	9 (22.0)
2	25 (31.3)	14 (35.9)	11 (26.8)
3	45 (56.3)	24 (61.5)	21 (51.2)

^aP < 0.05.

Data are n (%) unless otherwise indicated. BMI: Body mass index; LN: Lymph node; SD: Standard deviation.